Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report details a share repurchase transaction executed on June 20, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 1,200,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,471 pence per share; lowest price paid was 1,453.5 pence per share.
- Treasury Holdings (Settled): 467,007,927 shares (8.54% of total issued share capital).
- Treasury Holdings (Including Unsettled): 470,907,927 shares (9.42% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,999,143,060 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 1,200,000 shares. Consequently, the percentage of shares held in Treasury increased to 9.42% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 1,200,000 share repurchase based on the weighted average price between 1,453.5 and 1,471 pence.
- Confirm the impact of the 9.42% treasury holding on future earnings per share (EPS) calculations.
- Check subsequent filings for the settlement status of the 3,899,999 shares included in the "unsettled" treasury count.
- Review the remaining authorization limit for share buybacks under the May 3, 2012 shareholder mandate.